![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication June 27, 2005.
Revised September 27, 2005.
Accepted for publication September 27, 2005.
Hydrogen sulfide (H2S) functions as a neuromodulator, but whether it modulates visceral perception and pain is unknown. Cystathionine b-synthase (CBS) and cystathionine-g-liase (CSE) mediate enzymatic generation of H2S in mammalian cells. Here we have investigated the role of H2S in modulating nociception to colorectal distension, a model that mimics some features of the irritable bowel syndrome. Four graded (0.4-1.6 ml water) colorectal distensions (CRDs) were produced in conscious rats (healthy and post-colitic) and rectal nociception assessed by measuring the behavioural response during CRD. Healthy rats were administered with NaHS (as a source of H2S), L-cysteine or vehicle. In a second model we investigated nociception to CRD in rats recovering from a chemically induced acute colitis. We found that CBS and CSE are expressed in the colon and spinal cord. Treating rats with NaHS resulted in a dose-dependent attenuation of CRD-induced nociception with the maximal effect at 60 µmol/kg (p<0.05). Administration of L-cysteine, a CSE/CBS substrate, reduced rectal sensitivity to CRD (p<0.05). NaHS-induced antinociception was reversed by glibenclamide, a KATP channel inhibitor, and N
Nitro-L-arginine methyl ester hydrochloride, a nitric oxide (NO) synthase inhibitor. The antinociceptive effect of NaHS was maintained during the resolution of colon inflammation induced by intrarectal administration of a chemical irritant. In summary, these data show that H2S inhibits nociception induced by CRD in both healthy and post-colitic rats. This effect is mediated by KATP channels and NO. H2S-releasing drugs might be beneficial in treating painful intestinal disorders.
Key words:
H2S, Intestinal inflammation, KATP, Nitric oxide, Visceral pain, irritable bowel syndrome
This article has been cited by other articles:
![]() |
B. Andruski, D.-M. McCafferty, T. Ignacy, B. Millen, and J. J. McDougall Leukocyte trafficking and pain behavioral responses to a hydrogen sulfide donor in acute monoarthritis Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R814 - R820. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. C. Yong, S. W. Lee, C. S. Foo, K. L. Neo, X. Chen, and J.-S. Bian Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1330 - H1340. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Distrutti, L. Sediari, A. Mencarelli, B. Renga, S. Orlandi, G. Russo, G. Caliendo, V. Santagada, G. Cirino, J. L. Wallace, et al. 5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 447 - 458. [Abstract] [Full Text] [PDF] |
||||